Clinical outcomes
| . | Value (N = 456) . |
|---|---|
| Ibrutinib start date | 20 July 2010 to 4 December 2019 |
| Time on ibrutinib | |
| No. of discontinuations | 303 |
| Median (95% CI) | 42.9 (37.3-49.4) |
| Ibrutinib discontinuation, no. (%) | |
| No | 153 (34) |
| Yes | 303 (66) |
| Disease progression | 93 (31) |
| AE (not atrial fibrillation) | 96 (32) |
| AE (atrial fibrillation) | 19 (6) |
| Developed resistance | 11 (3) |
| Death | 39 (13) |
| Other, not specified | 45 (15) |
| PFS, mo | |
| Median (95% CI) | 70.0 (56.3-69.5) |
| OS, mo | |
| Median (95% CI) | 95.4 (86.0-not reached) |
| . | Value (N = 456) . |
|---|---|
| Ibrutinib start date | 20 July 2010 to 4 December 2019 |
| Time on ibrutinib | |
| No. of discontinuations | 303 |
| Median (95% CI) | 42.9 (37.3-49.4) |
| Ibrutinib discontinuation, no. (%) | |
| No | 153 (34) |
| Yes | 303 (66) |
| Disease progression | 93 (31) |
| AE (not atrial fibrillation) | 96 (32) |
| AE (atrial fibrillation) | 19 (6) |
| Developed resistance | 11 (3) |
| Death | 39 (13) |
| Other, not specified | 45 (15) |
| PFS, mo | |
| Median (95% CI) | 70.0 (56.3-69.5) |
| OS, mo | |
| Median (95% CI) | 95.4 (86.0-not reached) |
AE, adverse event.